Evaluation of costs in rheumatic diseases

Ruof, Jörg; Hülsemann, J. L.; Stucki, Gerold

doi:10.1097/00002281-199903000-00004

Cited by 24 publications

(17 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Current economic evaluations in the field of rheumatic diseases underline the need to include economic data in outcome assessment of clinical trials on rheumatoid arthritis (RA) and other musculoskeletal disorders (1)(2)(3). Since many evolving new therapies, such as biologic therapies, are costly, it is important to capture not only clinical data but additionally data on costs and their changes under therapy in order to render information on health economic effectiveness (1).…”

Section: Introductionmentioning

confidence: 99%

Indirect cost assessment in patients with rheumatoid arthritis (RA): Comparison of data from the health economic patient questionnaire HEQ‐RA and insurance claims data

Merkesdal

Ruof

Huelsemann

et al. 2005

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To render information on the accuracy of patient-reported indirect cost data compared with payer-derived data of the real indirect costs on a patient-by-patient basis concerning disease-related productivity losses in rheumatoid arthritis (RA). Methods. The assessment of indirect cost data was part of a clinical, multicenter, randomized RA trial. A total of 234 patients of working age with a diagnosis of RA (according to 1987 American College of Rheumatology criteria) were recruited. Demographics of the cohort were mean age 53 years, mean disease duration 8 years, 76% were women, and all had membership in the regional statutory health insurance plan. Every 3 months corresponding indirect cost data were derived for the cohort from a health economic questionnaire for cost assessment in patients with RA and the payer's database over a period of 18 months. Comparative statistical analyses were performed between patient-reported and insurance claims data. Results. The mean annual productivity losses due to sick leave amounted to 14 and 17 days per patient (questionnaire versus payer data), and productivity losses due to work disability amounted to 3 days (both); monetary valuation renders overall costs of €1,240 and €1,590, respectively. The difference of 17% in overall productivity losses is not significant. Comparison of productivity losses reveals a strong correlation of r ‫؍‬ 0.83 in those due to sick leave and of ‫؍‬ 0.84 in those due to work disability between questionnaire and payer data. Conclusion. The comparison of questionnaire and payer data shows that RA patients report their productivity losses adequately. Indirect cost assessment should therefore be included in further RA trials and observational studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Indirect cost assessment in patients with rheumatoid arthritis (RA): Comparison of data from the health economic patient questionnaire HEQ‐RA and insurance claims data

Merkesdal

Ruof

Huelsemann

et al. 2005

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…In einer 1999 durchgeführten Übersichtsarbeit wurden die Kostendatenquellen von 21 gesundheitsökonomischen Studien bei muskuloskelettalen Erkrankungen untersucht. Sieben Studien verwendeten eine patientenbezogene Kostenerhebung, 11 Arbeiten stützten sich auf ,objektive Kostendaten', die drei restlichen Arbeiten definierten die zu Grunde liegende Datenquelle nur unzureichend [11].…”

Section: Identifikation Der Kostendatenquelle(n)unclassified

“…Mögliche Gründe für diese Variabilität sind u.a. die fehlende Standardisierung der relevanten Kostendomänen und die Verwendung verschiedener objektiver (d. h. Abrechnungsdaten) und subjektiver (d. h. patienten-zentrierte Datenerhebung) Kostendatenquellen ohne systematische Analyse der Validität und Vergleichbarkeit derselben [11]. Im Rahmen eines Forschungsprojektes des Kompetenznetzes Rheumatologie konnten diese Fragestellungen empirisch bearbeitet werden.…”

Section: Introductionunclassified

Konzeptionelle und methodische Grundlagen von Krankheitskostenerhebungen in der Rheumatologie

et al. 2004

View full text Add to dashboard Cite

Cost-of-illness studies in rheumatic conditions show an enormous variability in reported costs. Reasons are-among others-a lack of standardization with regards to relevant cost domains and the utilization of various insufficiently validated costing sources. A flow scheme is presented which may serve as a systematic basis for a valid costing analysis. The scheme includes: i) Selection of relevant cost domains. A comprehensive matrix of cost domains may be used as a framework. According to the specific aims of any costing study individual domains might be selected. ii) An adequate level of detail has to be determined taking into account factors such as the validity of the data collection and the feasibility. iii) Appropriate objective (i. e. usage of administrative data) or subjective (i. e. patient-derived) data sources have to be identified under consideration of respective strengths and weaknesses. While administrative sources provide a valid access to costing data accessibility and feasibility are important advantages of patient-derived costing procedures. iv) During data collection the potential bias due to protocol-driven costs and the differentiation of disease-related from other health care costs should be considered. v) The data analysis should support a transparent presentation of the costing data both in physical and monetary units. In summary, no 'gold standard' has been established for costing studies yet. However, valid costing approaches might follow the flow scheme presented in this analysis.

show abstract

“…The extent of various health problems, especially osteoarthritis (OA) and osteoporosis (OP) in this case, must be correctly appreciated, and investigations on the respective burden of specific illnesses are required to quantify their relative significance. Economic evaluations of healthcare interventions in the field of rheumatology are now performed more frequently [1,2,3,4], and inclusion of cost assessment instruments is almost mandatory in clinical trials. group (DRG) based funding system in Germany from 2003 on, while various DRG systems have been instituted over the world starting in the early 1980s [6].…”

Section: Introductionmentioning

confidence: 99%

Implementing standardized cost categories within economic evaluations in musculoskeletal diseases

Mittendorf

Merkesdal

Huelsemann

et al. 2003

The European Journal of Health Economics

View full text Add to dashboard Cite

We present a matrix of relevant resource utilization domains for use in standardizing applied cost assessment in musculoskeletal conditions. In addition,we highlight the importance of selecting cost categories during the development of an economic evaluation. A set of four steps was applied: (a) literature search identifying economic evaluations in osteoarthritis and osteoporosis, (b) listing and aggregation of cost categories mentioned in the identified articles, (c) development of a matrix of resource utilization domains, and (d) qualitative discussion regarding the generalizability of the matrix to other musculoskeletal conditions such as rheumatoid arthritis. We examined 41 full-length articles (25 cost-of-illness studies or cost-comparisons, 14 cost-effectiveness analyses, and 2 cost-utility analyses), of which 16 studies focused on osteoarthritis and 25 on osteoporosis. The reviewed studies used a total of 151 different cost categories which, after adjustment for synonymous labeling, made up 34 cost categories. A matrix of 16 separate resource utilization domains was developed including seven outpatient, three inpatient, four other disease-related, and two productivity cost domains. We found that cost assessment in economic evaluation in the key musculo-skeletal diseases (osteoarthritis, osteoporosis, and rheumatoid arthritis) is performed rather inhomogeneously. A generalized matrix of applicable resource utilization domains and a flowchart facilitating the development of appropriate resource utilization data have been developed.

show abstract

Evaluation of costs in rheumatic diseases

Cited by 24 publications

References 13 publications

Indirect cost assessment in patients with rheumatoid arthritis (RA): Comparison of data from the health economic patient questionnaire HEQ‐RA and insurance claims data

Indirect cost assessment in patients with rheumatoid arthritis (RA): Comparison of data from the health economic patient questionnaire HEQ‐RA and insurance claims data

Konzeptionelle und methodische Grundlagen von Krankheitskostenerhebungen in der Rheumatologie

Implementing standardized cost categories within economic evaluations in musculoskeletal diseases

Contact Info

Product

Resources

About